Kelli Mccallum, P.T. ASSISTANT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1600 Charles Pl, Manhattan, KS 66502 Phone: 785-537-4200 Fax: 785-537-4354 |
Katelin Leinweber, P.T. ASSISTANT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1600 Charles Pl, Manhattan, KS 66502 Phone: 785-537-4200 Fax: 785-537-4354 |
Sara Mccarn, P.T. ASSISTANT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1600 Charles Pl, Manhattan, KS 66502 Phone: 785-537-4200 Fax: 785-537-4354 |
Jacob Dehn Vandervoort, PT, DPT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1133 College Ave Ste G200, Manhattan, KS 66502 Phone: 785-539-9669 |
Jeffrey C Joyce, R.P.T. Physical Medicine & Rehabilitation - Sports Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 Charles Pl, Manhattan, KS 66502 Phone: 785-537-4200 Fax: 785-537-4354 |
Michele Y. Dugan, R.P.T. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1600 Charles Place, Manhattan, KS 66502 Phone: 785-537-4200 Fax: 785-537-4354 |
News Archive
Although super-resolution light microscopy has broken new ground in our understanding of subcellular structures and the movement of individual molecules within cells, its use to investigate virus particles is in its infancy...
Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.
Drug makers are bracing for reform by raising their prices - by 9 percent in the last year, perhaps the fastest rate since 1992, The New York Times reports. This happened "even as drug makers promise to support Washington's health care overhaul by shaving $8 billion a year off the nation's drug costs after the legislation takes effect." The increases "will add more than $10 billion to the nation's drug bill, which is on track to exceed $300 billion this year."
Sanofi-aventis and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today that they have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies.
There are currently only two FDA-approved medications for the treatment of posttraumatic stress disorder (PTSD) in the United States. Both of these medications are serotonin uptake inhibitors. Despite the availability of these medications, many people diagnosed with PTSD remain symptomatic, highlighting the need for new medications for PTSD treatment.
› Verified 7 days ago